Financial Lp Hrt Buys 72,912 Shares of Aditxt (NASDAQ:ADTX) Stock

Aditxt, Inc. (NASDAQ:ADTX) major shareholder Financial Lp Hrt bought 72,912 shares of the stock in a transaction that occurred on Tuesday, April 21st. The stock was bought at an average price of $0.33 per share, with a total value of $24,060.96. Following the completion of the acquisition, the insider owned 133,574 shares of the company’s stock, valued at $44,079.42. This trade represents a 120.19% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, April 22nd, Financial Lp Hrt sold 11,982 shares of Aditxt stock. The shares were sold at an average price of $0.30, for a total transaction of $3,594.60.

Aditxt Stock Performance

Aditxt stock traded down $0.02 during trading on Thursday, reaching $0.29. The company had a trading volume of 605,118 shares, compared to its average volume of 849,327. Aditxt, Inc. has a 12-month low of $0.28 and a 12-month high of $2,495.04. The stock’s 50 day moving average price is $2.14 and its two-hundred day moving average price is $57.64. The firm has a market capitalization of $261,617.60, a price-to-earnings ratio of 0.00 and a beta of 1.74.

Aditxt (NASDAQ:ADTX) last released its earnings results on Tuesday, March 31st. The company reported $11,687.53 earnings per share (EPS) for the quarter. Aditxt had a negative net margin of 1,217,927.00% and a negative return on equity of 374.60%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aditxt in a report on Monday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Aditxt Company Profile

Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.